A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer.
Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D'Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C, Goossen H, Gounder V, Crosbie G, Hancock S, Diaz-Guilas S, Mainwaring P, Swindle P, Hart DN.
Prue RL, et al. Among authors: hardy my.
J Immunother. 2015 Feb-Mar;38(2):71-6. doi: 10.1097/CJI.0000000000000063.
J Immunother. 2015.
PMID: 25658616
Clinical Trial.